Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4

Alzheimer’s Disease Neuroimaging Initiative

doi:10.1002/alz.12797

Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4

Alzheimer’s Disease Neuroimaging Initiative

Research output: Contribution to journal › Review article › peer-review

Abstract

Introduction: The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. To improve generalizability, ADNI4 aims to enroll 50-60% of its new participants from underrepresented populations (URPs) using new biofluid and digital technologies. ADNI4 has received funding from the National Institute on Aging beginning September 2022. Methods: ADNI4 will recruit URPs using community-engaged approaches. An online portal will screen 20,000 participants, 4000 of whom (50-60% URPs) will be tested for plasma biomarkers and APOE. From this, 500 new participants will undergo in-clinic assessment joining 500 ADNI3 rollover participants. Remaining participants (∼3500) will undergo longitudinal plasma and digital cognitive testing. ADNI4 will add MRI sequences and new PET tracers. Project 1 will optimize biomarkers in AD clinical trials. Results and Discussion: ADNI4 will improve generalizability of results, use remote digital and blood screening, and continue providing longitudinal clinical, biomarker, and autopsy data to investigators.

Original language	English (US)
Pages (from-to)	307-317
Number of pages	11
Journal	Alzheimer's and Dementia
Volume	19
Issue number	1
DOIs	https://doi.org/10.1002/alz.12797
State	Published - Jan 2023

Keywords

Alzheimer's disease
amyloid
cerebrovascular disease
digital biomarkers
generalizability
mild cognitive impairment
plasma biomarkers
tau
underrepresented populations

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Cellular and Molecular Neuroscience
Psychiatry and Mental health

Access to Document

10.1002/alz.12797

Cite this

Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4. / Alzheimer’s Disease Neuroimaging Initiative.
In: Alzheimer's and Dementia, Vol. 19, No. 1, 01.2023, p. 307-317.

Research output: Contribution to journal › Review article › peer-review

@article{a1b240b79ae6447d9187c43b7588f16a,

title = "Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4",

abstract = "Introduction: The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. To improve generalizability, ADNI4 aims to enroll 50-60% of its new participants from underrepresented populations (URPs) using new biofluid and digital technologies. ADNI4 has received funding from the National Institute on Aging beginning September 2022. Methods: ADNI4 will recruit URPs using community-engaged approaches. An online portal will screen 20,000 participants, 4000 of whom (50-60% URPs) will be tested for plasma biomarkers and APOE. From this, 500 new participants will undergo in-clinic assessment joining 500 ADNI3 rollover participants. Remaining participants (∼3500) will undergo longitudinal plasma and digital cognitive testing. ADNI4 will add MRI sequences and new PET tracers. Project 1 will optimize biomarkers in AD clinical trials. Results and Discussion: ADNI4 will improve generalizability of results, use remote digital and blood screening, and continue providing longitudinal clinical, biomarker, and autopsy data to investigators.",

keywords = "Alzheimer's disease, amyloid, cerebrovascular disease, digital biomarkers, generalizability, mild cognitive impairment, plasma biomarkers, tau, underrepresented populations",

author = "{Alzheimer{\textquoteright}s Disease Neuroimaging Initiative} and Weiner, {Michael W.} and Veitch, {Dallas P.} and Miller, {Melanie J.} and Aisen, {Paul S.} and Bruce Albala and Beckett, {Laurel A.} and Green, {Robert C.} and Danielle Harvey and Jack, {Clifford R.} and William Jagust and Landau, {Susan M.} and Morris, {John C.} and Rachel Nosheny and Okonkwo, {Ozioma C.} and Perrin, {Richard J.} and Petersen, {Ronald C.} and Monica Rivera-Mindt and Saykin, {Andrew J.} and Shaw, {Leslie M.} and Toga, {Arthur W.} and Duygu Tosun and Trojanowski, {John Q.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",

year = "2023",

month = jan,

doi = "10.1002/alz.12797",

language = "English (US)",

volume = "19",

pages = "307--317",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Increasing participant diversity in AD research

T2 - Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4

AU - Alzheimer’s Disease Neuroimaging Initiative

AU - Weiner, Michael W.

AU - Veitch, Dallas P.

AU - Miller, Melanie J.

AU - Aisen, Paul S.

AU - Albala, Bruce

AU - Beckett, Laurel A.

AU - Green, Robert C.

AU - Harvey, Danielle

AU - Jack, Clifford R.

AU - Jagust, William

AU - Landau, Susan M.

AU - Morris, John C.

AU - Nosheny, Rachel

AU - Okonkwo, Ozioma C.

AU - Perrin, Richard J.

AU - Petersen, Ronald C.

AU - Rivera-Mindt, Monica

AU - Saykin, Andrew J.

AU - Shaw, Leslie M.

AU - Toga, Arthur W.

AU - Tosun, Duygu

AU - Trojanowski, John Q.

PY - 2023/1

Y1 - 2023/1

N2 - Introduction: The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. To improve generalizability, ADNI4 aims to enroll 50-60% of its new participants from underrepresented populations (URPs) using new biofluid and digital technologies. ADNI4 has received funding from the National Institute on Aging beginning September 2022. Methods: ADNI4 will recruit URPs using community-engaged approaches. An online portal will screen 20,000 participants, 4000 of whom (50-60% URPs) will be tested for plasma biomarkers and APOE. From this, 500 new participants will undergo in-clinic assessment joining 500 ADNI3 rollover participants. Remaining participants (∼3500) will undergo longitudinal plasma and digital cognitive testing. ADNI4 will add MRI sequences and new PET tracers. Project 1 will optimize biomarkers in AD clinical trials. Results and Discussion: ADNI4 will improve generalizability of results, use remote digital and blood screening, and continue providing longitudinal clinical, biomarker, and autopsy data to investigators.

AB - Introduction: The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. To improve generalizability, ADNI4 aims to enroll 50-60% of its new participants from underrepresented populations (URPs) using new biofluid and digital technologies. ADNI4 has received funding from the National Institute on Aging beginning September 2022. Methods: ADNI4 will recruit URPs using community-engaged approaches. An online portal will screen 20,000 participants, 4000 of whom (50-60% URPs) will be tested for plasma biomarkers and APOE. From this, 500 new participants will undergo in-clinic assessment joining 500 ADNI3 rollover participants. Remaining participants (∼3500) will undergo longitudinal plasma and digital cognitive testing. ADNI4 will add MRI sequences and new PET tracers. Project 1 will optimize biomarkers in AD clinical trials. Results and Discussion: ADNI4 will improve generalizability of results, use remote digital and blood screening, and continue providing longitudinal clinical, biomarker, and autopsy data to investigators.

KW - Alzheimer's disease

KW - amyloid

KW - cerebrovascular disease

KW - digital biomarkers

KW - generalizability

KW - mild cognitive impairment

KW - plasma biomarkers

KW - tau

KW - underrepresented populations

UR - http://www.scopus.com/inward/record.url?scp=85139685738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85139685738&partnerID=8YFLogxK

U2 - 10.1002/alz.12797

DO - 10.1002/alz.12797

M3 - Review article

C2 - 36209495

AN - SCOPUS:85139685738

SN - 1552-5260

VL - 19

SP - 307

EP - 317

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 1

ER -

Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this